First-in-class Thyromimetic MOA; activates hair follicle stem cells.
With dual IND approvals from both the FDA (January 2025) and CDE (March 2025), it is poised to enter first-in-human trials in the near term across multiple advanced solid tumor indications including HNSCC, Sarcoma, and Osteosarcoma. Phase 1 first-in-human trials are imminent, with Phase 2 initiation anticipated in late 2026.
Targets both the TH2 and TH1 pathways, the primary drivers of AD pathology. This differentiated dual-inhibitor approach is designed to deliver broader and more durable therapeutic response than single-pathway agents.
Novel mechanism targeting innate immune signaling at its molecular origin. A New Chemical Entity and the world's first small-molecule MyD88 inhibitor; set to enter clinical-stage compassionate use. Breakthrough results across multiple dermatological indications.
No competitor has reached clinical use with a small-molecule MyD88 inhibitor.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.